WO2002044358A3 - Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3 - Google Patents

Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3 Download PDF

Info

Publication number
WO2002044358A3
WO2002044358A3 PCT/US2001/044391 US0144391W WO0244358A3 WO 2002044358 A3 WO2002044358 A3 WO 2002044358A3 US 0144391 W US0144391 W US 0144391W WO 0244358 A3 WO0244358 A3 WO 0244358A3
Authority
WO
WIPO (PCT)
Prior art keywords
mtr
nucleic acid
cellular growth
provides
cancer
Prior art date
Application number
PCT/US2001/044391
Other languages
French (fr)
Other versions
WO2002044358A2 (en
Inventor
Mark Williamson
Original Assignee
Millennium Pharm Inc
Mark Williamson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Mark Williamson filed Critical Millennium Pharm Inc
Priority to AU2002232433A priority Critical patent/AU2002232433A1/en
Publication of WO2002044358A2 publication Critical patent/WO2002044358A2/en
Publication of WO2002044358A3 publication Critical patent/WO2002044358A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides novel MTR-3 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length MTR-3 proteins, the invention further provides isolated MTR-3 fusion proteins, antigenic peptides and anti-MTR-3 antibodies. The invention also provides MTR-3 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an MTR-3 gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of cellular growth or proliferation disorders, e.g., cancer, including, but not limited to colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular growth or proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular growth or proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular growth or proliferation disorder characterized by aberrant MTR-3 polypeptide activity or aberrant MTR-3 nucleic acid expression.
PCT/US2001/044391 2000-11-28 2001-11-28 Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3 WO2002044358A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002232433A AU2002232433A1 (en) 2000-11-28 2001-11-28 Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72459900A 2000-11-28 2000-11-28
US09/724,599 2000-11-28

Publications (2)

Publication Number Publication Date
WO2002044358A2 WO2002044358A2 (en) 2002-06-06
WO2002044358A3 true WO2002044358A3 (en) 2002-09-12

Family

ID=24911066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044391 WO2002044358A2 (en) 2000-11-28 2001-11-28 Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3

Country Status (2)

Country Link
AU (1) AU2002232433A1 (en)
WO (1) WO2002044358A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1402058A4 (en) * 2001-06-05 2006-02-01 Exelixis Inc Dgks as modifiers of the p53 pathway and methods of use
US20050196753A1 (en) * 2002-05-30 2005-09-08 Lata Jayaraman Human coactivator-associated arginine methyltransferase 1 (hCARM1)
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000594A2 (en) * 1998-06-30 2000-01-06 Incyte Pharmaceuticals, Inc. Human transferases
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000594A2 (en) * 1998-06-30 2000-01-06 Incyte Pharmaceuticals, Inc. Human transferases
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Regulation of transcription by a protein methyltransferase", SCIENCE, vol. 284, 25 June 1999 (1999-06-25), pages 2174 - 2177, XP002202230 *
DATABASE EMBL [online] 8 February 2001 (2001-02-08), CURAGEN CORP.: "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease", XP002202231, Database accession no. AAB43316 *

Also Published As

Publication number Publication date
AU2002232433A1 (en) 2002-06-11
WO2002044358A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
MXPA02001878A (en) Novel b74 molecules and uses therefor.
AU7599500A (en) Novel gl50 molecules and uses therefor
WO2001073060A3 (en) 18221, dual specificity phosphatase and uses thereof
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
ATE419358T1 (en) METHOD OF USE OF A NEW LYSYLOXIDASE-RELATED PROTEIN
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
WO2002070652A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2001000826A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO2000012544A3 (en) Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
WO2002044358A3 (en) Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3
WO2000008045A3 (en) Novel molecules of the tango-93-related protein family and uses thereof
WO2001030971A3 (en) Novel molecules and the card-related protein family and uses thereof
WO1999054437A3 (en) Novel molecules of the t125-related protein family and uses thereof
WO2001077151A3 (en) Fdrg proteins and nucleic acid molecules and uses therefor
WO2003029434A3 (en) Novel molecules of the hkid-1-related protein family and uses thereof
WO2002085939A8 (en) Novel molecules of the card-related protein family and uses thereof
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2000018890A3 (en) Protein phosphatase molecules and uses therefor
EA200300420A1 (en) Isolated nucleic acid molecules, isolated polypeptides AND METHOD FOR PRODUCTION THEREOF, METHOD FOR DETECTING THEM present in the sample (VARIANTS) host cell (VARIANTS) antibody kit (OPTIONS), a method of modulating activity of a polypeptide, IDENTIFICATION METHOD (VARIANTS) AND APPLICATION OF COMPOUNDS METHOD OF IDENTIFICATION OF THE SUBJECT (OPTIONS) AND METHOD OF TREATING THE SUBJECT WITH DAMAGE ASSOCIATED WITH POTASSIUM CHANNELS (OPTIONS)
WO2001083523A3 (en) Stmst protein and nucleic acid molecules and uses therefor
WO1999062943A3 (en) Novel molecules of the aip-related protein family and uses thereof
WO1999067387A3 (en) Novel mp-7 protein and nucleic acid molecules and uses therefor
WO2001059065A3 (en) Novel molecules of the card-related protein family and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP